CLOs on the Move

Amicus Therapeutics

www.amicusrx.com

 
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.amicusrx.com
  • 1 Cedar Brook Drive
    Cranbury, NJ USA 08512
  • Phone: 609.662.2000

Executives

Name Title Contact Details
Sergey Tesler
Executive Director, Global Regulatory Strategy, CMC Profile
Patrik Florencio
SVP, Global Chief Compliance and Risk Officer Profile
Ellen Rosenberg
Chief Legal Officer Profile
Heather Ramirez
Executive Director - Lead Counsel US Profile

Similar Companies

Universal Learning Approach

Sisu Stamina is a company that offers energy chews designed to enhance physical and cognitive performance. Their products are made with potent, clean ingredients to fuel the builders of tomorrow.

Medicine Hat Office

Medicine Hat Office is a Medicine Hat, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Hoss and Brown Engineers

Hoss and Brown Engineers is a Lawrence, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BHPI

At Behavioral Health Professionals, Inc. we take pride in offering expert behavioral health management services. It’s all we do.

Shire

At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions.To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.